# US 2015/0359871 A1 · Immunogenic compositions comprising silicified virus and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0359871 A1
- Document ID: US20150359871A1
- Status: Published application
- Kind: A1
- Application number: 14/763,947
- Filed: 2014-01-31
- Published: 2015-12-17
- Earliest claimed: 2013-01-31
- Assignees: Providence Health & Services - Oregon; Portland State University
- Applicants: Portland State University; Providence Health & Services-Oregon
- Inventors: Kenneth M. Stedman; James R. Laidler; Keith Bahjat
- Web page: https://patentgrep.com/patent/US20150359871A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/125: Picornaviridae, e.g. calicivirus
- A61K 39/13: Poliovirus
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/235: Adenoviridae
- A61K 39/285: Vaccinia virus or variola virus
- A61K 39/29: Hepatitis virus
- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- C12N 2710/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2720/12334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32421: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/32434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32621: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/32634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2795/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2795/14034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicified virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as a T cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant.

## Claims

### Claim 1

A method of inducing a virus-specific immune response in a subject, comprising administering to the subject an effective amount of silicified virus or silicified virus particles, thereby inducing a virus-specific immune response in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the virus is vaccinia virus, a rotavirus, an adenovirus, an influenza virus, a lentivirus, a flavivirus, a hepatitis virus, a picornavirus, or a coronavirus.

### Claim 3 (depends on 2)

The method of claim 2, wherein the lentivirus is an immunodeficiency virus.

### Claim 4 (depends on 3)

The method of claim 3, wherein the immunodeficiency virus is a human immunodeficiency virus.

### Claim 5 (depends on 2)

The method of claim 2, wherein the flavivirus is West Nile virus, Japanese encephalitis virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, or St. Louis encephalitis virus.

### Claim 6 (depends on 2)

The method of claim 2, wherein the hepatitis virus is hepatitis A virus, hepatitis B virus or hepatitis C virus.

### Claim 7 (depends on 2)

The method of claim 2, wherein the picornavirus is poliovirus.

### Claim 8 (depends on 2)

The method of claim 2, wherein the coronavirus is severe acute respiratory syndrome (SARS) virus or Middle East respiratory syndrome (MERS) coronavirus.

### Claim 9 (depends on 1)

The method of claim 1, wherein the virus-specific immune response comprises activation of virus-specific T cells, production of virus-specific antibodies, cytokine production, or any combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein administration is by a route selected from intramuscular, subcutaneous, oral and inhalation.

### Claim 11

An immunogenic composition comprising (i) a silicified virus or silicified virus particles and (ii) a pharmaceutically acceptable carrier or an adjuvant, wherein the virus is vaccinia virus, a rotavirus, an adenovirus, an influenza virus, a lentivirus, a flavivirus, a hepatitis virus, a picornavirus or a coronavirus.

### Claim 12 (depends on 11)

The immunogenic composition of claim 11, wherein
the lentivirus is an immunodeficiency virus;
the flavivirus is West Nile virus, Japanese encephalitis virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, or St. Louis encephalitis virus;
the hepatitis virus is hepatitis A virus, hepatitis B virus or hepatitis C virus;
the picornavirus is poliovirus; or
the coronavirus is SARS virus or MERS virus.

### Claim 13 (depends on 12)

The immunogenic composition of claim 12, wherein the immunodeficiency virus is a human immunodeficiency virus.

### Claim 14 (depends on 11)

The immunogenic composition of claim 11, wherein the adjuvant comprises a water-in-oil emulsion, incomplete Freund's adjuvant, alum, aluminum hydroxide, a toll-like receptor agonist, an immunostimulatory oligonucleotide or a biological adjuvant.

### Claim 15 (depends on 11)

The immunogenic composition of claim 11, wherein the pharmaceutically acceptable carrier comprises physiological saline, balanced salt solution, buffering agent, suspending agent, thickening agent, non-aqueous solvent, aqueous carrier, preservative, anti-oxidant, bacateriostat, or any combination thereof.

### Claim 16 (depends on 11)

The immunogenic composition of claim 11, contained in unit-dose form.

### Claim 17

A method of enhancing a virus-specific cell-mediated immune response in a subject, comprising administering to the subject a silicified virus or silicified virus particles, wherein the virus-specific cell-mediated immune response is increased relative to the cell-mediated immune response following administration of non-silicified virus or non-silicified virus particles.

### Claim 18 (depends on 17)

The method of claim 17, wherein the virus is vaccinia virus, a rotavirus, an adenovirus, an influenza virus, a lentivirus, a flavivirus, a hepatitis virus, a picornavirus, or a coronavirus.

### Claim 19 (depends on 18)

The method of claim 18, wherein:
the lentivirus is an immunodeficiency virus;
the flavivirus is West Nile virus, Japanese encephalitis virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, or St. Louis encephalitis virus;
the hepatitis virus is hepatitis A virus, hepatitis B virus or hepatitis C virus;
the picornavirus is poliovirus; or
the coronavirus is SARS virus or MERS virus.

### Claim 20 (depends on 19)

The method of claim 19, wherein the immunodeficiency virus is a human immunodeficiency virus.

### Claim at position 21

21-22. (canceled)